• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌促凝物质的分离与特性:一种来自恶性组织的半胱氨酸蛋白酶。

Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.

作者信息

Falanga A, Gordon S G

出版信息

Biochemistry. 1985 Sep 24;24(20):5558-67. doi: 10.1021/bi00341a041.

DOI:10.1021/bi00341a041
PMID:3935163
Abstract

Cancer procoagulant, a proteolytic procoagulant enzyme, has been purified from rabbit V2 carcinoma extracts by two procedures. In the first, the protein was purified by benzamidine--Sepharose affinity chromatography, gel filtration chromatography, and phenyl-Sepharose hydrophobic chromatography. Antiserum was raised against the purified protein and was used to prepare an immunoadsorbent column. In the second, tumor extracts were purified by immunoaffinity chromatography followed by p-(chloromercuri)benzoate affinity chromatography. The second procedure was substantially quicker and easier. The final product of both procedures was homogeneous on the basis of analytical sodium dodecyl sulfate--polyacrylamide gel electrophoresis and isoelectric focusing. The molecular weight was 68 000 and the isoelectric point 4.8. The proteinase activity of cancer procoagulant directly activated factor X, in the absence of factor VII, and was inhibited by 1 mM iodoacetamide and 0.1 mM mercury which are classic cysteine proteinase inhibitors. A carbohydrate analysis showed less than 1 mol of hexose or sialic acid/mol of protein. The amino acid analysis showed that serine (19.1%), glycine (18.77%), and glutamic acid (12.5%) were the prevalent amino acids. The amino acid composition of cancer procoagulant was substantially different than other known factor X activating proteinases or other cysteine proteinases including cathepsin B.

摘要

癌促凝素是一种蛋白水解促凝酶,已通过两种方法从兔V2癌提取物中纯化出来。第一种方法是,通过苯甲脒-琼脂糖亲和色谱、凝胶过滤色谱和苯基-琼脂糖疏水色谱对该蛋白进行纯化。用纯化后的蛋白制备抗血清,并用于制备免疫吸附柱。第二种方法是,先通过免疫亲和色谱,再通过对氯汞苯甲酸亲和色谱对肿瘤提取物进行纯化。第二种方法要快得多且更简便。两种方法的最终产物在分析型十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和等电聚焦的基础上均呈均一状态。其分子量为68000,等电点为4.8。癌促凝素的蛋白酶活性在无因子VII的情况下可直接激活因子X,并被1 mM碘乙酰胺和0.1 mM汞抑制,这两种物质是典型的半胱氨酸蛋白酶抑制剂。碳水化合物分析显示,每摩尔蛋白中己糖或唾液酸含量不到1摩尔。氨基酸分析表明,丝氨酸(19.1%)、甘氨酸(18.77%)和谷氨酸(12.5%)是主要氨基酸。癌促凝素的氨基酸组成与其他已知的因子X激活蛋白酶或其他半胱氨酸蛋白酶(包括组织蛋白酶B)有很大不同。

相似文献

1
Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.癌促凝物质的分离与特性:一种来自恶性组织的半胱氨酸蛋白酶。
Biochemistry. 1985 Sep 24;24(20):5558-67. doi: 10.1021/bi00341a041.
2
A factor X-activating cysteine protease from malignant tissue.一种来自恶性组织的X因子激活半胱氨酸蛋白酶。
J Clin Invest. 1981 Jun;67(6):1665-71. doi: 10.1172/jci110203.
3
Cysteine proteinase procoagulant from amnion-chorion.来自羊膜-绒毛膜的半胱氨酸蛋白酶促凝剂。
Blood. 1985 Dec;66(6):1261-5.
4
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.几种具有转移特性的小鼠肿瘤都有一种具有癌促凝特性的半胱氨酸蛋白酶。
Int J Cancer. 1987 Jun 15;39(6):774-7. doi: 10.1002/ijc.2910390620.
5
Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant.癌促凝素与人类羊膜绒毛促凝素特性的比较。
Biochim Biophys Acta. 1985 Sep 20;831(1):161-5. doi: 10.1016/0167-4838(85)90165-7.
6
[Proteinases of small intestine enterocytes of swine. Purification and properties of aspartyl proteinase similar to cathepsin D].[猪小肠肠上皮细胞的蛋白酶。与组织蛋白酶D相似的天冬氨酸蛋白酶的纯化及特性]
Biokhimiia. 1985 Sep;50(9):1453-62.
7
A proteolytic procoagulant associated with malignant transformation.一种与恶性转化相关的蛋白水解促凝剂。
J Histochem Cytochem. 1981 Mar;29(3A Suppl):457-63. doi: 10.1177/29.3.457.
8
gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant.
Haemostasis. 1986;16(3-4):295-9. doi: 10.1159/000215301.
9
The purification and properties of cancer procoagulant from murine tumors.源自鼠类肿瘤的癌促凝剂的纯化及特性
Biochem Biophys Res Commun. 1992 Apr 30;184(2):819-24. doi: 10.1016/0006-291x(92)90663-6.
10
Purification and partial characterization of an acid proteinase from Dirofilaria immitis.犬恶丝虫酸性蛋白酶的纯化及部分特性分析
Mol Biochem Parasitol. 1993 Apr;58(2):293-9. doi: 10.1016/0166-6851(93)90051-x.

引用本文的文献

1
Clinical guidelines for prevention and treatment of CAT in Japan and other countries.日本和其他国家的 CAT 预防和治疗临床指南。
Int J Hematol. 2024 May;119(5):505-515. doi: 10.1007/s12185-024-03736-w. Epub 2024 Apr 1.
2
Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis.血管性肝脏疾病的分子机制:聚焦于血栓形成。
Int J Mol Sci. 2023 Aug 13;24(16):12754. doi: 10.3390/ijms241612754.
3
Procoagulant genes may affect angiogenesis, epithelial-mesenchymal transition, survival prognosis and tumor immune microenvironment in patients with urothelial carcinoma.
促凝基因可能影响尿路上皮癌患者的血管生成、上皮-间充质转化、生存预后和肿瘤免疫微环境。
Aging (Albany NY). 2023 Jul 8;15(13):6429-6444. doi: 10.18632/aging.204860.
4
Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer.肿瘤基因组特征与实体癌患者的动脉血栓栓塞风险相关。
JACC CardioOncol. 2023 Apr 18;5(2):246-255. doi: 10.1016/j.jaccao.2023.01.009. eCollection 2023 Apr.
5
[Cancer-associated stroke: a study of prevalence and predictors among ischaemic stroke patients].[癌症相关性卒中:缺血性卒中患者中的患病率及预测因素研究]
Rev Neurol. 2023 Mar 16;76(6):189-195. doi: 10.33588/rn.7606.2022414.
6
Low antithrombin levels are associated with low risk of cardiovascular death but are a risk factor for cancer mortality.抗凝血酶水平低与心血管死亡风险低有关,但却是癌症死亡的一个风险因素。
PLoS One. 2022 Sep 19;17(9):e0271663. doi: 10.1371/journal.pone.0271663. eCollection 2022.
7
Successful Treatment of Recurrent Thrombosis Associated with Malignancy with Apixaban and Follow-up for 1 Year.阿哌沙班成功治疗与恶性肿瘤相关的复发性血栓形成并随访1年
Int J Angiol. 2020 Dec;29(4):256-259. doi: 10.1055/s-0039-1694780. Epub 2019 Aug 7.
8
Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.血液恶性肿瘤弥漫性血管内凝血的诊断与治疗进展。
Int J Hematol. 2021 Jan;113(1):34-44. doi: 10.1007/s12185-020-02992-w. Epub 2020 Sep 9.
9
Plasma Concentrations of High Molecular Weight Kininogen and Prekallikrein and Venous Thromboembolism Incidence in the General Population.血浆高分子量激肽原和前激肽释放酶浓度与普通人群静脉血栓栓塞发生率的关系。
Thromb Haemost. 2019 May;119(5):834-843. doi: 10.1055/s-0039-1678737. Epub 2019 Feb 19.
10
Analysis of the role of thrombomodulin in all-trans retinoic acid treatment of coagulation disorders in cancer patients.血栓调节蛋白在全反式维甲酸治疗癌症患者凝血障碍中的作用分析。
Theor Biol Med Model. 2019 Feb 14;16(1):3. doi: 10.1186/s12976-019-0099-z.